Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Operations (2016 - 2025)

Rocket Pharmaceuticals' Cash from Operations history spans 10 years, with the latest figure at 34840000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 25.78% year-over-year to 34840000.0; the TTM value through Dec 2025 reached 190014000.0, up 9.4%, while the annual FY2025 figure was 190014000.0, 9.4% up from the prior year.
  • Cash from Operations for Q4 2025 was 34840000.0 at Rocket Pharmaceuticals, up from 50420000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 24283000.0 in Q1 2021 and bottomed at 57560000.0 in Q1 2023.
  • The 5-year median for Cash from Operations is 47953000.0 (2024), against an average of 44697950.0.
  • The largest annual shift saw Cash from Operations tumbled 136.03% in 2021 before it surged 47.63% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 30941000.0 in 2021, then crashed by 81.06% to 56021000.0 in 2022, then soared by 47.63% to 29339000.0 in 2023, then tumbled by 60.0% to 46942000.0 in 2024, then grew by 25.78% to 34840000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Cash from Operations are 34840000.0 (Q4 2025), 50420000.0 (Q3 2025), and 48964000.0 (Q2 2025).